Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin

被引:30
作者
Gimpl, G
Postina, R
Fahrenholz, F
Reinheimer, T
机构
[1] Johannes Gutenberg Univ Mainz, Inst Biochem, D-55099 Mainz, Germany
[2] Ferring Pharmaceut AS, Dept Nonclin Dev, DK-2300 Copenhagen, Denmark
关键词
atosiban; barusiban; carbetocin; G-protein coupled receptors; oxytocin;
D O I
10.1016/j.ejphar.2005.01.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V-IA/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin. For this purpose, chimeric 'gain-in function' oxytocin/vasopressin V-2 receptors were expressed in COS-7 cells. These recombinant receptors have been produced by transfer of domains from the oxytocin receptor into the related vasopressin V-2 receptor and have already been successfully employed for the identification of ligand binding domains at the oxytocin receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996. Separate agonist and peptide antagonist binding sites of the oxytocin receptor defined by their transfer into the V-2 vasopressin receptor. J. Biol. Chem. 271, 3159331601). In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands oxytocin, [Arg(8)]vasopressin, carbetocin, and atosiban. The binding profiles for the agonists oxytocin and carbetocin were found to be similar. For both agonists, important binding domains were the extracellular N-terminus (=E1) and the extracellular loops E2 and E3 from the oxytocin receptor., For the vasopressin VIA/oxytocin receptor antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V-2 receptor. In contrast, the binding of barusiban was significantly improved when the transmembrane domains 1 and 2 were transferred from the oxytocin receptor to the vasopressin V-2 receptor. The binding domain of barusiban differs from the binding domain of the agonists and the nonselective oxytocin receptor antagonist d(CH2)(5)[Tyr(Me)(2) Th-4,Orn(8),Tyr(9)]vasotocin that has been used in previous studies. Overall, the data supported the concept of a central pocket site within the oxytocin receptor. (c) 2005 Elsevier B.V All rights reserved.
引用
收藏
页码:9 / 16
页数:8
相关论文
共 18 条
  • [1] Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women
    Åkerlund, M
    Bossmar, T
    Brouard, R
    Kostrzewska, A
    Laudanski, T
    Lemancewicz, A
    Serradeil-Le Gal, C
    Steinwall, M
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1999, 106 (10): : 1047 - 1053
  • [2] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [3] Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist -: Comparison with the human V1a vasopressin receptor
    Breton, C
    Chellil, H
    Kabbaj-Benmansour, M
    Carnazzi, E
    Seyer, R
    Phalipou, S
    Morin, D
    Durroux, T
    Zingg, H
    Barberis, C
    Mouillac, B
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (29) : 26931 - 26941
  • [4] I-125-LABELED D(CH2)5[TYR(ME)2,THR4,TYR-NH2(9)]OVT - A SELECTIVE OXYTOCIN RECEPTOR LIGAND
    ELANDS, J
    BARBERIS, C
    JARD, S
    TRIBOLLET, E
    DREIFUSS, JJ
    BANKOWSKI, K
    MANNING, M
    SAWYER, WH
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 147 (02) : 197 - 207
  • [5] Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation
    Engstrom, T
    Barth, T
    Melin, P
    Vilhardt, H
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 355 (2-3) : 203 - 210
  • [6] Activation mechanism of human oxytocin receptor: A combined study of experimental and computer-simulated mutagenesis
    Fanelli, F
    Barbier, P
    Zanchetta, D
    De Benedetti, PG
    Chini, B
    [J]. MOLECULAR PHARMACOLOGY, 1999, 56 (01) : 214 - 225
  • [7] The Oxytocin Receptor System: Structure, function, and regulation
    Gimpl, G
    Fahrenholz, F
    [J]. PHYSIOLOGICAL REVIEWS, 2001, 81 (02) : 629 - 683
  • [8] MOLECULAR-CLONING AND FUNCTIONAL-CHARACTERIZATION OF V2 [8-LYSINE] VASOPRESSIN AND OXYTOCIN RECEPTORS FROM A PIG-KIDNEY CELL-LINE
    GORBULEV, V
    BUCHNER, H
    AKHUNDOVA, A
    FAHRENHOLZ, F
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1993, 215 (01): : 1 - 7
  • [9] Identification of an extracellular segment of the oxytocin receptor providing agonist-specific binding epitopes
    Hawtin, SR
    Howard, HC
    Wheatley, M
    [J]. BIOCHEMICAL JOURNAL, 2001, 354 : 465 - 472
  • [10] The role of N-terminal glycosylation in the human oxytocin receptor
    Kimura, T
    Makino, Y
    Bathgate, R
    Ivell, R
    Nobunaga, T
    Kubota, Y
    Kumazawa, I
    Saji, F
    Murata, Y
    Nishihara, T
    Hashimoto, M
    Kinoshita, M
    [J]. MOLECULAR HUMAN REPRODUCTION, 1997, 3 (11) : 957 - 963